Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
tanespimycin · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Tanespimycin + Bortezomib |
| Arm B | ACTIVE_COMPARATOR | Bortezomib |
| tanespimycin and bortezomib | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin. |
| bortezomib and tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin. |
| bortezomib tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin. |
| A1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tanespimycin | DRUG | Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion |
| Bortezomib | DRUG | Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus |
Inclusion Criteria: * Good Performance Status * Documented evidence of multiple myeloma * Documented progression of disease after initial response to one line of therapy * Measurable disease (serum M-protein \>.5g/dl or \> 200 mg urinary M protein excretion) Exclusion Criteria: * Prior treatment ...
Top 20 of 25 competitors
Tanespimycin is an investigational small molecule being studied for the treatment of solid tumors, advanced malignancies, and multiple myeloma. It has been evaluated in clinical trials for patients with relapsed or refractory multiple myeloma and for solid tumors, including HER2 positive metastatic breast cancer.
Tanespimycin is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company has sponsored clinical trials of the drug in patients with multiple myeloma and solid tumors.
Tanespimycin has been studied in Phase 1, Phase 2, and Phase 3 clinical trials. However, it is not approved by the FDA and remains an investigational agent. All completed trials have finished, and there are no active trials currently listed.
Tanespimycin has been studied in several completed trials, including NCT00514371 in relapsed or refractory multiple myeloma, NCT00546780 in first relapse multiple myeloma, NCT00773344 in solid tumors and HER2 positive metastatic breast cancer, and NCT00779428 as a continuation study for advanced malignancies.
Yes, Tanespimycin is also known as KOS-953. Clinical trial titles refer to the drug as Tanespimycin (KOS-953), confirming that these names refer to the same investigational agent.